Enveric Biosciences

04/24/2026

Hallucinations associated with classic psychedelics can carry significant psychological, physiological and clinical challenges. Enveric is advancing EB-003, a first-in-class neuroplastogen that has the potential to treat mental health disorders without inducing hallucinations, making the treatment more accessible, scalable, and clinically practical. Find out more about our novel approach: https://bit.ly/3jyBy8o

04/21/2026

Our CEO, Joseph Tucker, Ph.D., will participate in a panel discussion at Needham’s upcoming Virtual Psychedelics Forum. The panel, “Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications,” will take place on Monday, April 27, from 1:00 PM - 2:00 PM ET. For event details: https://bit.ly/4cALg4X

04/18/2026

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://bit.ly/3Qt6Y3p

04/01/2026

Our CEO, Joseph Tucker, PhD, comments on the Company’s new U.S. patent covering its EVM301 Series of molecules, including lead candidate EB-003, being developed as a potential treatment for mental health disorders. For more info: https://bit.ly/4tjrD87

03/31/2026

Enveric Biosciences has received U.S. Patent No. 12,577,232 (“the’232 patent”) from the USPTO pertaining to its EVM301 Series of molecules which includes lead candidate, EB-003. The patent provides added depth to Enveric’s EVM301 IP portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. For details: https://bit.ly/4tjrD87

03/28/2026

Enveric today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. See it here: https://bit.ly/4bCMVrz

03/19/2026

Our CEO, Joseph Tucker, Ph.D., comments on the registration of five trademarks that supports Enveric’s branding strategy for its future products. Learn more: https://bit.ly/4buehyK

03/18/2026

Enveric Biosciences announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences, as well as two “Plus Marks” which are designs used on Enveric product packaging, and its trademark, “Next Generation Mental Health.” For more details: https://bit.ly/4buehyK

03/10/2026

Our CEO, Joseph Tucker, sat down with Drug Discovery Online to discuss the shift in neuropsychiatric drug development toward neuroplastogens and Enveric’s lead candidate EB-003, which has been found to activate Gq- and β-arrestin signaling pathways linked to therapeutic-related brain biology. Read the interview here: https://bit.ly/46Ru89a

We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.

03/02/2026

A recent article in PharmaTech News details how the withdrawal of the Post Grant Review petition against Enveric’s ’276 patent reframes the neuroplastogen race and reinforces its positioning as a company with a strong IP foundation in next-generation, psychedelic-inspired drug development. Read it here:

In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court.

02/27/2026

Enveric’s CEO, Joseph Tucker, explains the potential benefits of EB-003's dual mechanism that selectively engages both the 5-HT2A and 5-HT1B receptors to promote neuroplasticity without triggering unwanted effects. Learn more in Drug Discovery News: https://bit.ly/3MQCUgH

02/27/2026

Medium details new insight into how Enveric's next-generation neuroplastogens, EB-003, may separate the therapeutic benefits of psychedelics from hallucinogenic effects, potentially making treatment for neuropsychiatric disorders more accessible. https://bit.ly/3Mowqpk